Yan Lu, Liu Yibin, Zhang Zhiqiang, Du Feida
Department of Gynecology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, People's Republic of China.
J Multidiscip Healthc. 2025 Jul 25;18:4197-4217. doi: 10.2147/JMDH.S526280. eCollection 2025.
Immunotherapy-based treatment has shown significant clinical potential in various cancers. This study provides a comprehensive bibliometric analysis of the immunotherapy landscape in ovarian cancer over the last decade, identifying leading trends, influential contributors, and key areas of development.
A systematic literature search was conducted in the Web of Science Core Collection for publications on immunotherapy drugs used in ovarian cancer between 2014 and 2024. Analytical tools such as VOSviewer, CiteSpace, and the R-based Bibliometrix package were employed to visualize trends, collaborations, and major contributions.
Our dataset of 2123 publications from 2014 to 2024 highlights a rise and stabilization in publication output, peaking in 2022. Leading journals included and . Although a recent decline was observed, it may reflect a shift toward refining existing therapies rather than initiating new studies. The United States and China were major contributors, with institutions such as Harvard University, University of California, and Fudan University leading in output. European institutions like Charité Berlin and KU Leuven also played prominent roles, with key researchers including Sehouli J, Vergote I, and Scambia G. Highly cited studies included The Cancer Genome Atlas, which identified critical genetic mutations in high-grade serous ovarian cancer, and landmark trials exploring the addition of bevacizumab to standard therapies. These works emphasize ongoing challenges such as genetic heterogeneity and resistance, driving research toward biomarker-based and personalized therapeutic strategies. Thematic clustering revealed a progression from foundational treatment trials to precision medicine, with focus areas including platinum resistance and neoadjuvant therapies.
This bibliometric analysis maps the growing research interest in immunotherapy-based approaches for ovarian cancer, highlighting the field's collaborative and multidisciplinary nature. The findings provide a foundation for identifying influential themes and guiding future investigations into resistance mechanisms and personalized treatment strategies.
基于免疫疗法的治疗在多种癌症中已显示出显著的临床潜力。本研究对过去十年卵巢癌免疫治疗领域进行了全面的文献计量分析，确定了主要趋势、有影响力的贡献者以及关键发展领域。
在Web of Science核心合集中进行了系统的文献检索，以查找2014年至2024年间关于卵巢癌免疫治疗药物的出版物。使用VOSviewer、CiteSpace和基于R的Bibliometrix软件包等分析工具来可视化趋势、合作情况和主要贡献。
我们2014年至2024年的2123篇出版物数据集显示，出版物数量呈上升并趋于稳定，在2022年达到峰值。主要期刊包括《》和《》。尽管最近有所下降，但这可能反映了研究方向从开展新研究转向优化现有疗法。美国和中国是主要贡献者，哈佛大学、加利福尼亚大学和复旦大学等机构在产出方面领先。柏林夏里特医院和鲁汶大学等欧洲机构也发挥了重要作用，关键研究人员包括Sehouli J、Vergote I和Scambia G。被高度引用的研究包括《癌症基因组图谱》，该研究确定了高级别浆液性卵巢癌中的关键基因突变，以及探索在标准疗法中添加贝伐单抗的标志性试验。这些研究强调了基因异质性和耐药性等持续存在的挑战，推动了基于生物标志物和个性化治疗策略的研究。主题聚类显示从基础治疗试验到精准医学的进展，重点领域包括铂耐药和新辅助治疗。
本文献计量分析描绘了对基于免疫疗法的卵巢癌治疗方法日益增长的研究兴趣，突出了该领域的合作性和多学科性质。研究结果为确定有影响力的主题以及指导未来对耐药机制和个性化治疗策略的研究提供了基础。
